Allergan acquires QLT acne treatment
US drugmaker Allergan has acquired the rights to Aczone (dapsone) topical gel, for the treatment of acne, from the US arm of Canada's QLT for $150.0 million.
Allergan will receive all assets relating to the product upon closing, which is expected to occur in the third quarter of this year. The firm predicts Aczone could achieve peak annual revenue of $75.0 million.
Aczone 5% gel is approved in the USA and Canada for the treatment of acne vulgaris in patients aged 12 and over. It has already demonstrated safety and efficacy in 3,000 patients during two randomized, double-blind, vehicle-controlled clinical studies, according to the firm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze